MichaelBJordanMD

Pediatric Hematology & Oncology • Cincinnati, OH

Associate Professor, Pediatrics, University of Cincinnati College of Medicine

Join to view full profile

Dr. Jordan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jordan's full profile

Already have an account?

Office
3333 Burnet Ave
# ML5021
Cincinnati, OH 45229
Phone+1 513-636-9985

Fax+1 866-213-7089

Education & Training

University of ColoradoFellowship, Pediatric Hematology/Oncology, 1996 - 2002
University of Texas Southwestern Medical CenterResidency, Pediatrics, 1993 - 1996
University of Texas Southwestern Medical SchoolClass of 1993

Certifications & Licensure

OH State Medical License 2004 - 2026
CO State Medical License 1996 - 2009
TX State Medical License 1995 - 1997
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Start of enrollment: 2010 Apr 01
Completed
Phase 2
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis Start of enrollment: 2013 Jul 01
Completed
Phase 2, Phase 3
A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody Start of enrollment: 2014 Aug 04
Completed
Phase 2, Phase 3
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease Start of enrollment: 2021 Jul 14
RECRUITING
PHASE2
INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH) Start of enrollment: 2021 Dec 31
RECRUITING
Roles: Principal Investigator, Study Chair, Contact
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Start of enrollment: 2016 Nov 02
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome.
Adi Zoref-Lorenz, Thomas E Witzig, James R Cerhan, Michael B Jordan
Leukemia & Lymphoma. 2025-04-01
1 citations
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review St...
Shanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, John Carter, May Chien
Arthritis & Rheumatology. 2025-02-01
PRMT5 Inhibition Reduces Hyperinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis (HLH).
Fiona Brown-Burke, Rachel Saadey, Hsiao-Yin Charlene Charlene Mao, Paola Marra, Eric Brooks
Blood Advances. 2025-01-18

Journal Articles

Review and Feature Article Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the...
Michael Jordan, MD, ScienceDirect
Extending Remission and Reversing New Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T Cells
Michael B Jordan, Jonathan D Katz, Diabetes Care

Lectures

Hemophagocytic Lymphohistiocytosis: New Treatment Horizons
60th American Society of Hematology Annual Meeting - 11/30/2018

Grant Support

Hybrid Immunotherapy (Atg/Dexamethasone/Etoposide) For Hemophagocytic LymphohistiNational Heart, Lung, And Blood Institute2012
An Animal Model Of Hemophagocytic LymphohistiocytosisNational Heart, Lung, And Blood Institute2010–2011
An Animal Model Of Hemophagocytic LymphohistiocytosisNational Heart, Lung, And Blood Institute2007–2009
B Cell Expansion After Dendritic Cell ImmunizationNational Institute Of Allergy And Infectious Diseases2004
B Cell Expansion After Dendritic Cell ImmunizationNational Institute Of Allergy And Infectious Diseases2002–2003